| ISIN | LU1334634299 |
|---|---|
| Valorennummer | 30671916 |
| Bloomberg Global ID | |
| Fondsname | Crossfund Sicav-Crossinvest Healthcare Fund A USD |
| Fondsanbieter |
Crossinvest SA
Lugano, Schweiz Telefon: +41 91 911 88 88 E-Mail: info@crossinvest.ch Web: www.crossinvest.ch |
| Fondsanbieter | Crossinvest SA |
| Vertreter in der Schweiz |
FundPartner Solutions (Suisse) SA Genève 75 |
| Distributor(en) |
FundPartner Solutions (Suisse) SA Genève 3 |
| Anlagekategorie | Aktienfonds |
| EFC-Kategorie | |
| Anteilskategorie | Accumulation |
| Domizilland | Luxemburg |
| Konditionen bei der Ausgabe | Kombination von Ausgabekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
| Konditionen bei der Rücknahme | Kombination von Rücknahmekommission zugunsten der Fondsleitung und Transaktionsgebühr zugunsten des Fonds |
| Investment-Strategie *** | The investment objective of the Sub‐Fund is to achieve a long term capital appreciation by pursuing sector focus exposure opportunities in companies involved in health and personal care. These companies could participate in the research, clinical development or commercialization of medicines, equipment or services for disease treatment or life style improvement. The investment focus will be on industry leaders that offer premium growth and/or profitability prospects, pipeline and valuation upside. The Sub‐Fund is actively managed. The Sub‐Fund has no benchmark index and is not managed in reference to a benchmark index. |
| Besonderheiten |
| Aktueller Preis * | 171.00 USD | 16.01.2026 |
|---|---|---|
| Vorheriger Preis * | 171.46 USD | 15.01.2026 |
| 52 Wochen Hoch * | 173.51 USD | 07.01.2026 |
| 52 Wochen Tief * | 141.13 USD | 07.08.2025 |
| NAV * | 171.00 USD | 16.01.2026 |
| Ausgabepreis * | 171.00 USD | 16.01.2026 |
| Rücknahmepreis * | ||
| Schlusskurs * | ||
| Indikativer Minimalpreis | ||
| Fondsvermögen *** | 54'793'175 | |
| Anteilsklassevermögen *** | 12'194'324 | |
| Trading Information SIX | ||
| YTD-Performance | +1.53% |
31.12.2025 - 16.01.2026
31.12.2025 16.01.2026 |
|---|---|---|
| YTD-Performance (in CHF) | +2.76% |
31.12.2025 - 16.01.2026
31.12.2025 16.01.2026 |
| 1 Monat | +2.75% |
16.12.2025 - 16.01.2026
16.12.2025 16.01.2026 |
| 3 Monate | +10.36% |
16.10.2025 - 16.01.2026
16.10.2025 16.01.2026 |
| 6 Monate | +15.92% |
16.07.2025 - 16.01.2026
16.07.2025 16.01.2026 |
| 1 Jahr | +10.95% |
16.01.2025 - 16.01.2026
16.01.2025 16.01.2026 |
| 2 Jahre | +8.03% |
16.01.2024 - 16.01.2026
16.01.2024 16.01.2026 |
| 3 Jahre | +9.80% |
16.01.2023 - 16.01.2026
16.01.2023 16.01.2026 |
| 5 Jahre | +10.49% |
18.01.2021 - 16.01.2026
18.01.2021 16.01.2026 |
| Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Eli Lilly and Co | 7.57% | |
|---|---|---|
| Novartis AG Registered Shares | 4.59% | |
| AbbVie Inc | 4.46% | |
| Novo Nordisk AS Class B | 4.27% | |
| UnitedHealth Group Inc | 4.18% | |
| Roche Holding AG | 3.91% | |
| Essilorluxottica | 3.78% | |
| AstraZeneca PLC | 3.51% | |
| Abbott Laboratories | 3.28% | |
| Merck & Co Inc | 3.28% | |
| Letzte Daten-Aktualisierung | 30.09.2025 | |
| TER *** | 2.123% |
|---|---|
| Datum TER *** | 30.11.2025 |
| Performance Fee *** | 15.00% |
| PTR | |
| Max. Management Fee *** | 1.50% |
| Ongoing Charges *** | |
|
SRRI ***
|
|
| Datum SRRI *** | 31.12.2025 |